

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

Phospho-Bcr (Tyr177) Antibody

RRID:AB_2063779

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3901, RRID:AB_2063779

Antibody Information

URL: http://antibodyregistry.org/AB_2063779

Proper Citation: Cell Signaling Technology Cat# 3901, RRID:AB_2063779

Target Antigen: Bcr, phospho (Tyr177)

Clonality: unknown

Comments: Applications: W, F

Antibody Name: Phospho-Bcr (Tyr177) Antibody

Description: This unknown targets Bcr, phospho (Tyr177)

Target Organism: mouse, human

Antibody ID: AB_2063779

Vendor: Cell Signaling Technology

Catalog Number: 3901

Record Creation Time: 20250819T205927+0000

Record Last Update: 20250819T212920+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Bcr (Tyr177) Antibody.

No alerts have been found for Phospho-Bcr (Tyr177) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lernoux M, et al. (2020) Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Clinical epigenetics, 12(1), 69.

Wei L, et al. (2020) A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway. Molecular therapy oncolytics, 18, 137.